DAFNA Capital Management LLC Sells 36,675 Shares of Brainsway Ltd. Sponsored ADR $BWAY

Key Points

• DAFNA Capital Management LLC has reduced its holdings in Brainsway Ltd. by 19% during Q1, selling 36,675 shares and now owning approximately 156,533 shares valued at $1.48 million.
• Brainsway Ltd. reported earnings of $0.10 per share for the latest quarter, exceeding analysts' expectations, and set a price target with a consensus of $18.00 among equities analysts.
• Shares of Brainsway have shown significant price fluctuations, with a 52-week low of $7.06 and a high of $16.00, and currently trade at $15.56 with a market cap of $294.08 million.

DAFNA Capital Management LLC reduced its position in Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY - Free Report) by 19.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 156,533 shares of the company's stock after selling 36,675 shares during the quarter. DAFNA Capital Management LLC owned about 0.83% of Brainsway worth $1,482,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Two Sigma Investments LP raised its stake in shares of Brainsway by 2.0% during the fourth quarter. Two Sigma Investments LP now owns 92,755 shares of the company's stock worth $875,000 after acquiring an additional 1,786 shares in the last quarter. Cubist Systematic Strategies LLC boosted its holdings in Brainsway by 14.6% in the fourth quarter. Cubist Systematic Strategies LLC now owns 19,228 shares of the company's stock valued at $181,000 after acquiring an additional 2,446 shares in the last quarter. Lazard Asset Management LLC bought a new stake in shares of Brainsway during the 4th quarter valued at $44,000. GAMMA Investing LLC boosted its holdings in shares of Brainsway by 720.7% during the 1st quarter. GAMMA Investing LLC now owns 9,356 shares of the company's stock valued at $89,000 after buying an additional 8,216 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in Brainsway by 61.9% in the 4th quarter. JPMorgan Chase & Co. now owns 23,918 shares of the company's stock worth $226,000 after purchasing an additional 9,149 shares in the last quarter. 30.11% of the stock is owned by hedge funds and other institutional investors.

Brainsway Stock Performance

Shares of NASDAQ BWAY opened at $15.56 on Friday. Brainsway Ltd. Sponsored ADR has a fifty-two week low of $7.06 and a fifty-two week high of $16.00. The company has a market cap of $294.08 million, a PE ratio of 59.85 and a beta of 1.42. The business has a 50-day simple moving average of $12.88 and a two-hundred day simple moving average of $10.85.

Brainsway (NASDAQ:BWAY - Get Free Report) last released its earnings results on Wednesday, August 13th. The company reported $0.10 EPS for the quarter, topping analysts' consensus estimates of $0.07 by $0.03. Brainsway had a return on equity of 8.97% and a net margin of 11.60%.The firm had revenue of $12.63 million during the quarter, compared to the consensus estimate of $12.34 million. Brainsway has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Brainsway Ltd. Sponsored ADR will post 0.08 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on BWAY shares. Northland Securities boosted their target price on Brainsway from $15.00 to $19.00 and gave the stock an "outperform" rating in a research report on Thursday, August 14th. HC Wainwright reiterated a "buy" rating and set a $17.00 price objective on shares of Brainsway in a research note on Monday, August 25th. Finally, Wall Street Zen upgraded Brainsway from a "hold" rating to a "buy" rating in a research note on Sunday, August 17th. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $18.00.

Brainsway Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.

Want to see what other hedge funds are holding BWAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.